Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study comparing pharmacokinetics, safety, and tolerability of FYB202 with reference drug Stelara

Trial Profile

A clinical study comparing pharmacokinetics, safety, and tolerability of FYB202 with reference drug Stelara

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Immunological disorders
  • Focus Adverse reactions
  • Sponsors Bioeq
  • Most Recent Events

    • 28 Oct 2019 According to a Formycon media release, dosing of study subjects in this trial started last week. Bioeq GmbH is the sponsor of the clinical trial and is also responsible for the study design and clinical operation.
    • 28 Oct 2019 Status changed from planning to recruiting, as reported in a Formycon media release.
    • 06 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top